Avere Therapeutics to Go Public via Reverse Merger with NextCure, Advances Psoriasis Pill
Privately held biopharma company Avere Therapeutics is set to go public through a reverse merger with NextCure. The deal includes $320 million in new funding and aims to advance AVR-001, an experimental psoriasis pill licensed from Hansoh Pharma that could compete with AbbVie's Skyrizi and Johnson & Johnson’s Icotyde.
Topics: drug development pharma M&A psoriasis treatment reverse merger